Clinical Trial Detail

NCT ID NCT03839446
Title Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Michael Boyiadzis
Indications

acute myeloid leukemia

Therapies

Etoposide + Gemtuzumab ozogamicin + Mitoxantrone

Age Groups: adult senior

No variant requirements are available.